醛脱氢酶抑制剂与BRCA突变驱动肿瘤的化学预防的潜在作用
本文探讨醛脱氢酶1A家族抑制剂(ALDHi)能否在肿瘤起始阶段靶向癌症起始细胞,从而用于卵巢癌化学预防。研究发现BRCA突变卵巢癌细胞及BRCA1敲低的输卵管上皮细胞对673A更敏感,673A可降低小鼠输卵管类器官复杂度并显著减少BRCA突变细胞集落形成,在BPRN小鼠模型中显著减少浆液性输卵管上皮内癌(STIC)病变和癌。
要点
- BRCA突变卵巢癌细胞较BRCA野生型细胞对ALDHi 673A更敏感。
- 673A对野生型输卵管上皮细胞无毒性,但可诱导BRCA1敲低的输卵管上皮细胞死亡。
- 在BPRN小鼠模型中,间歇性673A治疗显著减少STIC病变和癌。
核心结论
- 研究结果提示,如673A等ALDHi可能作为BRCA1/2突变携带者的化学预防剂。
研究设计与样本
- 研究采用BRCA突变相关肿瘤细胞系和小鼠肿瘤模型,包括小鼠输卵管类器官致癌模型及BPRN(Brca1、Trp53、Rb1、Nf1失活)小鼠输卵管卵巢癌模型。
主要发现
- 与BRCA野生型细胞相比,BRCA突变卵巢癌细胞对ALDHi 673A更敏感。
- 673A处理野生型输卵管上皮(FTE)细胞无毒性,但可诱导BRCA1敲低的FTE细胞死亡。
- 在小鼠输卵管类器官致癌模型中,673A降低类器官复杂度并显著减少BRCA突变细胞的集落形成。
- 673A处理后存留的类器官以BRCA1野生型但NF1突变为主,提示一种耐药机制。
- 在BPRN小鼠模型中,间歇性673A治疗显著减少浆液性输卵管上皮内癌(STIC)病变和癌。
临床怎么用
- 作者认为,如673A等ALDHi可能作为BRCA1/2突变携带者的化学预防剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aldehyde dehydrogenase (ALDH) enzymatic activity is a marker of cancer-initiating cells (CIC) in many tumor types. Our group and others have found that ALDH1A family inhibitors (ALDHi) can preferentially induce death of ovarian CIC in established ovarian cancer. We sought to determine if ALDHi, by targeting CIC at the time of tumor initiation, could function as a chemopreventive for ovarian cancer. As BRCA1/2 mutation carriers represent a population who could benefit from an ovarian cancer chemopreventive, we focused on BRCA mutation-associated tumor cell lines and murine tumor models. We found that, compared to BRCA wild-type cells, BRCA mutant ovarian cancer cells are more sensitive to the ALDHi673A. Similarly, while 673A treatment of wild-type fallopian tube epithelial (FTE) cells is non-toxic, 673A induces death in FTE cells with BRCA1 knockdown. Using a murine fallopian tube organoid model of ovarian carcinogenesis, we show that 673A reduced organoid complexity and significantly reduce colony formation of BRCA-mutant cells. Organoids that persisted after 673A treatment were predominantly BRCA1wt, but NF1 mutant, suggesting a resistance mechanism. Finally, using the BPRN (Brca1, Trp53, Rb1, Nf1 inactivated) mouse model of tubo-ovarian cancer, we evaluated the impact of intermittent 673A therapy on carcinogenesis. 673A treatment resulted in a significant reduction in serous tubal intraepithelial carcinoma (STIC) lesions and carcinomas. Collectively, the findings suggest that ALDHi, such as 673A, could serve as chemopreventive agents for BRCA1/2 mutation carriers.
引用
- McGonigal S, Wu R, Grimley E, et al. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors. Gynecol Oncol. 2023. PMID: 37535994. doi:10.1016/j.ygyno.2023.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。